Argenx Receives EU Approval for VYVGART Subcutaneous Injection

argenx gets EU nod for Vyvgart subcutaneous injection

Argenx receives EU approval for VYVGART subcutaneous injection

argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy

**media[660557]**

Argenx Gets European Commission Approval For Drug To Treat Rare Autoimmune Disease, But Stock Fails To Garner Retail Attention

Argenx Secures EC Approval for Subcutaneous VYVGART in CIDP Treatment

Argenx (NASDAQ:ARGX) is one of the best biotech stocks to invest in now.

European Commission Approves Efgartigimod Subcutaneous Injection for Forms of CIDP

Efgartigimod alfa SC is now approved in Europe for patients with chronic inflammatory demyelinating polyneuropathy, following a positive recommendation from the Committee for Medicinal Products for Human Use.